VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age over 18 years                                  │ Age over 18 years                                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ General Condition WHO 0, 1 or 2                    │ General Condition WHO 0, 1 or 2                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ASA Class I and II, eligible for endoscopic or     │ ASA Class I and II, eligible for endoscopic or     │     100 │
│ surgical treatment with curative intent            │ surgical treatment with curative intent            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histological diagnosis of high grade glandular     │ Histological diagnosis of high grade glandular     │     100 │
│ epithelial neoplasia (Vienna 4-1 to 4-46),         │ epithelial neoplasia (Vienna 4-1 to 4-46),         │         │
│ possibly multifocal or stage 0 (Tis, N0, M0)       │ possibly multifocal or stage 0 (Tis, N0, M0)       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Endoscopic and histological confirmed diagnosis of │ Endoscopic and histological confirmed diagnosis of │     100 │
│ intestinal metaplasia                              │ intestinal metaplasia                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histological diagnosis confirmed by two            │ Histological diagnosis confirmed by two            │     100 │
│ endoscopies with biopsies and two pathological     │ endoscopies with biopsies and two pathological     │         │
│ readings; biopsies should be carried out according │ readings; biopsies should be carried out according │         │
│ to the protocol of the SFED (four-quadrant         │ to the protocol of the SFED (four-quadrant         │         │
│ biopsies every cm) with at least once acetic acid  │ biopsies every cm) with at least once acetic acid  │         │
│ for staining. Operators describe Barrett's         │ for staining. Operators describe Barrett's         │         │
│ esophagus using he SFED planimetric model. The     │ esophagus using he SFED planimetric model. The     │         │
│ final exam will be no more than two months before  │ final exam will be no more than two months before  │         │
│ the date of treatment and should have been         │ the date of treatment and should have been         │         │
│ achieved in investigator establishment             │ achieved in investigator establishment             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Minimum 1 cm                                       │ Minimum 1 cm                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Maximum 12 cm                                      │ Maximum 12 cm                                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ resection should be more than two months           │ resection should be more than two months           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ resection must have been macroscopically complete  │ resection must have been macroscopically complete  │     100 │
│ laterally                                          │ laterally                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ resection must have been histologically complete   │ resection must have been histologically complete   │     100 │
│ in depth                                           │ in depth                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ resection must have been histologically complete   │ resection must have been histologically complete   │     100 │
│ laterally with regard to the microinvasive cancer, │ laterally with regard to the microinvasive cancer, │         │
│ that is to say with a clear margin of safety       │ that is to say with a clear margin of safety       │         │
│ (margin may be high-grade dysplasia provided that  │ (margin may be high-grade dysplasia provided that  │         │
│ the latter has not macroscopic translation)        │ the latter has not macroscopic translation)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At least one endoscopic and histologic follow-up   │ At least one endoscopic and histologic follow-up   │     100 │
│ should be conducted with dye in a period of less   │ should be conducted with dye in a period of less   │         │
│ than two months before the date of treatment, and  │ than two months before the date of treatment, and  │         │
│ at the investigator establishment                  │ at the investigator establishment                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient may take an inhibitor of proton pump       │ Patient may take an inhibitor of proton pump       │     100 │
│ equivalent to 2 times 40 mg of esomeprazole        │ equivalent to 2 times 40 mg of esomeprazole        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No mediastinal or celiac, or suspected metastatic  │ No mediastinal or celiac, or suspected metastatic  │     100 │
│ lymph nodes by EUS                                 │ lymph nodes by EUS                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Affiliation to a social security system or similar │ Affiliation to a social security system or similar │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lack of participation in another clinical study    │ Lack of participation in another clinical study    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed consent signed                            │ Informed consent signed                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lack of informed consent signed                    │ Lack of informed consent signed                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Radiofrequency treatment history                   │ Radiofrequency treatment history                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ on going neoplastic history with a short prognosis │ on going neoplastic history with a short prognosis │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant participation in another clinical      │ Concomitant participation in another clinical      │     100 │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication to general anesthesia             │ Contraindication to general anesthesia             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with an esophageal location of scleroderma │ Patient with an esophageal location of scleroderma │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of a cardiac pacemaker or stimulator      │ Presence of a cardiac pacemaker or stimulator      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant women or likely to be in the absence of   │ Pregnant women or likely to be in the absence of   │     100 │
│ effective contraception                            │ effective contraception                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Esophageal stenosis preventing the passage of an   │ Esophageal stenosis preventing the passage of an   │     100 │
│ endoscope                                          │ endoscope                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histology other than glandular neoplasia           │ Histology other than glandular neoplasia           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of or current history of esophageal cancer │ History of or current history of esophageal cancer │     100 │
│ invading the submucosal layer of the esophagus or  │ invading the submucosal layer of the esophagus or  │         │
│ more                                               │ more                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Surgical treatment history (except anti-reflux     │ Surgical treatment history (except anti-reflux     │     100 │
│ treatment) or esophageal radiotherapy              │ treatment) or esophageal radiotherapy              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ previous esophageal treatment by another method    │ previous esophageal treatment by another method    │     100 │
│ ablation: photodynamic therapy, argon plasma       │ ablation: photodynamic therapy, argon plasma       │         │
│ coagulation, laser,                                │ coagulation, laser,                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Esophageal varices observed in endoscopy           │ Esophageal varices observed in endoscopy           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy of less than 3 years, due to       │ Life expectancy of less than 3 years, due to       │     100 │
│ intercurrent disease, especially neoplastic        │ intercurrent disease, especially neoplastic        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver cirrhosis (Child-Pugh all stages)            │ Liver cirrhosis (Child-Pugh all stages)            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Respiratory failure                                │ Respiratory failure                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Heart attack within the last six months or         │ Heart attack within the last six months or         │     100 │
│ progressive coronary artery disease                │ progressive coronary artery disease                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ - Aged under 18                                    │ Aged under 18                                      │      93 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ the resected lesion must have been well            │ the resected lesion must have been well            │      96 │
│ differentiated and confined to the muscular mucosa │ differentiated and confined to the mucosa (m2      │         │
│ (m3 maximum) on histological analysis              │ maximum) on histological analysis                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal failure (Cl Cr \< 60 mL /min /1,73m²)        │ Renal failure (Cl Cr < 60 mL /min /1,73m)          │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Coagulopathy or taking anticoagulants responsible  │ Coagulopathy or taking anticoagulants responsible  │      99 │
│ an INR\> 1.3 or a platelet count \<75,000 per      │ an INR> 1.3 or a platelet count <75,000 per microL │         │
│ microL                                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe distal arteriopathie \> stage II of Leriche │ Severe distal arteriopathie > stage II of Leriche  │      99 │
│ and Fontaine                                       │ and Fontaine                                       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ PaCO2\> 45 mmHg                                    │ Maximum 12 cm                                      │      29 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PaO2 \<60 mmHg                                     │ Maximum 12 cm                                      │      30 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ VEMS (Maximum Expiratory Volume Second) \<1L / min │ Maximum 12 cm                                      │      35 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe Medical pathology                           │ Severe distal arteriopathie > stage II of Leriche  │      42 │
│                                                    │ and Fontaine                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Extension height of Barrett's esophagus upstream   │ History of or current history of esophageal cancer │      44 │
│ of the upper part of the gastric folds or palisade │ invading the submucosal layer of the esophagus or  │         │
│ vessels                                            │ more                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In case of previous treatment by mucosal resection │ previous esophageal treatment by another method    │      46 │
│ or submucosal dissection (DSM) for severe          │ ablation: photodynamic therapy, argon plasma       │         │
│ dysplasia or microinvasive carcinoma               │ coagulation, laser,                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Age over 18 years                                  │      48 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 94
Average Levenshtein Ratio of individual lines: 90.8125
OverAll Ratio: 92.40625
